Moreover, a study of clinical breast cancer patients receiving neoadjuvant chemotherapy treatment (NACT) demonstrates that higher ADAM10 protein level before NACT was associated with poor response to NACT and shorter overall survival. This evidence concerns the gene ADAM10 and breast carcinoma.